Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors

Blood Cancer J. 2019 Mar 29;9(4):43. doi: 10.1038/s41408-019-0203-y.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • STAT3 Transcription Factor / antagonists & inhibitors*

Substances

  • Protein Kinase Inhibitors
  • STAT3 Transcription Factor
  • STAT3 protein, human